172 related articles for article (PubMed ID: 26293672)
21. Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer.
Möller K; Kluth M; Ahmed M; Burkhardt L; Möller-Koop C; Büscheck F; Weidemann S; Tsourlakis MC; Minner S; Heinzer H; Huland H; Graefen M; Sauter G; Schlomm T; Dum D; Simon R
Int J Cancer; 2021 Feb; 148(3):748-758. PubMed ID: 33045100
[TBL] [Abstract][Full Text] [Related]
22. A physical, transcript, and deletion map of chromosome region 12p12.3 flanked by ETV6 and CDKN1B: hypermethylation of the LRP6 CpG island in two leukemia patients with hemizygous del(12p).
Baens M; Wlodarska I; Corveleyn A; Hoornaert I; Hagemeijer A; Marynen P
Genomics; 1999 Feb; 56(1):40-50. PubMed ID: 10036184
[TBL] [Abstract][Full Text] [Related]
23. Chromosome microarray characterisation of chromosome arm 12p loss associated with complex molecular karyotype and recurrent adverse cytogenetic markers in multiple myeloma.
Hung D; Lenton D; Eslick R; Blennerhassett R; Joshi M; McCaughan G; Day S; Wright D
Genes Chromosomes Cancer; 2021 Oct; 60(10):668-677. PubMed ID: 34041820
[TBL] [Abstract][Full Text] [Related]
24. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
[TBL] [Abstract][Full Text] [Related]
25. HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.
Zabalza CV; Adam M; Burdelski C; Wilczak W; Wittmer C; Kraft S; Krech T; Steurer S; Koop C; Hube-Magg C; Graefen M; Heinzer H; Minner S; Simon R; Sauter G; Schlomm T; Tsourlakis MC
Oncotarget; 2015 May; 6(14):12822-34. PubMed ID: 25825985
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
28. Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer.
Melling N; Taskin B; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Heinzer H; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Schlomm T; Krech T
Prostate; 2016 Feb; 76(3):259-72. PubMed ID: 26764246
[TBL] [Abstract][Full Text] [Related]
29. Analysis of chromosome 12p deletion in plasma cell dyscrasias.
Jiang N; Qi C; Yu L; Ning Y; An G; Qiu L; Chang H
Leuk Res; 2012 Jan; 36(1):32-6. PubMed ID: 21982640
[TBL] [Abstract][Full Text] [Related]
30. High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer.
Melling N; Harutyunyan L; Hube-Magg C; Kluth M; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Steurer S; Izbicki J; Sauter G; Wilczak W; Schlomm T; Krech T
PLoS One; 2015; 10(7):e0134614. PubMed ID: 26230842
[TBL] [Abstract][Full Text] [Related]
31. HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.
Burdelski C; Ruge OM; Melling N; Koop C; Simon R; Steurer S; Sauter G; Kluth M; Hube-Magg C; Minner S; Wittmer C; Wilczak W; Hinsch A; Lebok P; Izbicki JR; Heinzer H; Graefen M; Huland H; Schlomm T; Krech T
Exp Mol Pathol; 2015 Jun; 98(3):419-26. PubMed ID: 25794974
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
33. The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy.
Bramhecha YM; Rouzbeh S; Guérard KP; Scarlata E; Brimo F; Chevalier S; Hamel L; Aprikian AG; Lapointe J
Mod Pathol; 2019 Jan; 32(1):128-138. PubMed ID: 30140035
[TBL] [Abstract][Full Text] [Related]
34. High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.
Heumann A; Heinemann N; Hube-Magg C; Lang DS; Grupp K; Kluth M; Minner S; Möller-Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Wittmer C; Jacobsen F; Huland H; Simon R; Schlomm T; Sauter G; Steurer S; Lebok P; Hinsch A
BMC Cancer; 2018 Jan; 18(1):37. PubMed ID: 29304771
[TBL] [Abstract][Full Text] [Related]
35. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
Stumm L; Burkhardt L; Steurer S; Simon R; Adam M; Becker A; Sauter G; Minner S; Schlomm T; Sirma H; Michl U
J Clin Pathol; 2013 Jul; 66(7):563-8. PubMed ID: 23559350
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer.
Kluth M; Meyer D; Krohn A; Freudenthaler F; Bauer M; Salomon G; Heinzer H; Michl U; Steurer S; Simon R; Sauter G; Schlomm T; Minner S
Oncotarget; 2016 Jan; 7(4):3897-904. PubMed ID: 26684029
[TBL] [Abstract][Full Text] [Related]
37. Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
Burdelski C; Barreau Y; Simon R; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Sauter G; Wittmer C; Steurer S; Adam M; Huland H; Schlomm T; Tsourlakis MC; Quaas A
Hum Pathol; 2015 Apr; 46(4):514-23. PubMed ID: 25701228
[TBL] [Abstract][Full Text] [Related]
38. 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy.
Fromont G; Godet J; Peyret A; Irani J; Celhay O; Rozet F; Cathelineau X; Cussenot O
Hum Pathol; 2013 Aug; 44(8):1617-23. PubMed ID: 23574779
[TBL] [Abstract][Full Text] [Related]
39. Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis.
Sirma H; Broemel M; Stumm L; Tsourlakis T; Steurer S; Tennstedt P; Salomon G; Michl U; Haese A; Simon R; Sauter G; Schlomm T; Minner S
Oncol Lett; 2013 Nov; 6(5):1245-1252. PubMed ID: 24179503
[TBL] [Abstract][Full Text] [Related]
40. 5q21 deletion is often heterogeneous in prostate cancer.
Kluth M; Al Kilani Z; Özden C; Hussein K; Frogh S; Möller-Koop C; Burandt E; Steurer S; Büscheck F; Jacobsen F; Luebke AM; Minner S; Tsourlakis MC; Hoeflmayer D; Wittmer C; Schlomm T; Sauter G; Simon R; Wilczak W
Genes Chromosomes Cancer; 2019 Aug; 58(8):509-515. PubMed ID: 30623509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
